T2 Biosystems
Developing a medical diagnostic platform that enables rapid and accurate diagnostic tests of all types on a single instrument.
Launch date
Employees
Market cap
AUD64.5m
Enterprise valuation
AUD88m (Public information from Sep 2024)
Share price
€1.905 3T2.F
Lexington Kentucky (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 18.0m | 28.0m | 22.0m | 7.2m | 10.6m | 23.1m | 33.3m |
| % growth | 125 % | 56 % | (21 %) | (67 %) | 47 % | 118 % | 44 % |
| EBITDA | (38.0m) | (39.1m) | (53.6m) | (46.8m) | - | - | - |
| % EBITDA margin | (211 %) | (140 %) | (244 %) | (650 %) | - | - | - |
| Profit | (47.0m) | (49.0m) | (63.0m) | (50.1m) | (43.0m) | (40.7m) | (39.2m) |
| % profit margin | (261 %) | (175 %) | (286 %) | (696 %) | (406 %) | (176 %) | (118 %) |
| EV / revenue | 10.2x | 3.1x | 0.5x | 3.5x | 5.3x | 2.4x | 1.7x |
| EV / EBITDA | -4.8x | -2.2x | -0.2x | -0.5x | - | - | - |
| R&D budget | 16.1m | 21.8m | 25.8m | 14.2m | - | - | - |
| R&D % of revenue | 90 % | 78 % | 117 % | 197 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$40.0m | Series E | ||
| N/A | $57.0m | IPO | |
* | N/A | $34.1m | Post IPO Equity |
| N/A | $40.0m Valuation: $200m | Post IPO Equity | |
$50.0m | Post IPO Debt | ||
$2.0m | Grant | ||
$69.0m | Grant | ||
* | $3.7m | Grant | |
* | $15.0m | Post IPO Convertible | |
* | N/A | $8.0m | Private Placement VC |
| Total Funding | AUD274m | ||
Related Content
Recent News about T2 Biosystems
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.